Focus: Magellan is a public biotechnology company focused on stem cell-derived therapies for musculoskeletal diseases, with a lead Phase 3 program in allogeneic mesenchymal stem cells for knee osteoarthritis. The company is headquartered in Wallace, ID and operates across cell therapy and related health technology platforms.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Hot — 28 jobs added in 30d
Net +21 (28 new, 7 removed). Aggressive expansion phase.
Only pursue if you have high risk tolerance and believe in the stem cell thesis; the financial runway is critically short and hiring may not reflect true stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Magellan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Magellan's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo